These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24388125)

  • 1. Hepatic portal venous gas: a rare complication of malignant bowel obstruction during the administration of octreotide.
    Maeda I; Tsuneto S; Yasui Y; Ueda Y; Kimura T
    J Pain Symptom Manage; 2014 Feb; 47(2):e2-5. PubMed ID: 24388125
    [No Abstract]   [Full Text] [Related]  

  • 2. How to use octreotide for malignant bowel obstruction.
    Ripamonti C; Mercadante S
    J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of octreotide in malignant bowel obstruction.
    Krammer LM
    Oncol Nurs Forum; 1999 Jun; 26(5):831-2. PubMed ID: 10382174
    [No Abstract]   [Full Text] [Related]  

  • 4. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
    Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
    Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Octreotide may prevent definitive intestinal obstruction.
    Mercadante S; Kargar J; Nicolosi G
    J Pain Symptom Manage; 1997 Jun; 13(6):352-5. PubMed ID: 9204656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide for malignant bowel obstruction: twenty years after.
    Mercadante S; Porzio G
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide in malignant intestinal obstruction.
    Pandha HS; Waxman J
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():5-10. PubMed ID: 8822079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer.
    Peng X; Wang P; Li S; Zhang G; Hu S
    World J Surg Oncol; 2015 Feb; 13():50. PubMed ID: 25889313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiological imaging change in a malignant bowel obstruction patient treated with octreotide.
    Shinjo T; Kagami R
    Support Care Cancer; 2009 Jun; 17(6):753-5. PubMed ID: 19277723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction.
    Mercadante S
    J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021
    [No Abstract]   [Full Text] [Related]  

  • 11. Intrahepatic portal venous gas as a sequel to invasive ovarian adenocarcinoma.
    Dardik H; Mitsudo SM; Gilmore EC; Dardik I
    Am J Gastroenterol; 1971 Mar; 55(3):273-6. PubMed ID: 5578091
    [No Abstract]   [Full Text] [Related]  

  • 12. The challenge of treating malignant bowel obstruction.
    J Support Oncol; 2006 Feb; 4(2):83-4. PubMed ID: 16499129
    [No Abstract]   [Full Text] [Related]  

  • 13. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients.
    Mercadante S; Avola G; Maddaloni S; Salamone G; Aragona F; Rodolico V
    Support Care Cancer; 1996 Sep; 4(5):393-4. PubMed ID: 8883235
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
    Uchino R; Kusano S; Hanada N; Ohara C; Okino T; Yamaguchi K
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):255-7. PubMed ID: 21368489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
    Watanabe H; Inoue Y; Uchida K; Okugawa Y; Hiro J; Ojima E; Kobayashi M; Miki C; Kusunoki M
    J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
    Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
    Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer.
    Jatoi A; Podratz KC; Gill P; Hartmann LC
    J Support Oncol; 2004; 2(4):323-34; discussion 334-7. PubMed ID: 15357517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical Therapy of Malignant Bowel Obstruction With Octreotide, Dexamethasone, and Metoclopramide.
    Berger J; Lester P; Rodrigues L
    Am J Hosp Palliat Care; 2016 May; 33(4):407-10. PubMed ID: 25646530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
    Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
    Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Octreotide for malignant bowel obstruction: commentary on Currow et al.
    Mercadante S
    J Pain Symptom Manage; 2015 May; 49(5):813. PubMed ID: 25863013
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.